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Background: Continuous escalation in methodological and procedural rigor for evidence-based processes in
guideline development is associated with increasing costs and production delays that threaten sustainability.
While health research methodologists are appropriately responsible for promoting increasing rigor in guideline
development, guideline sponsors are responsible for funding such processes.
Discussion: This paper acknowledges that other stakeholders in addition to methodologists should be more
involved in negotiating trade-offs between methodological procedures and efficiency in guideline production to
produce guidelines that are ‘good enough’ to be trustworthy and affordable under specific circumstances. The
argument for reasonable methodological compromise to meet practical circumstances is consistent with current
implicit methodological practice. This paper proposes a conceptual tool as a framework to be used by different
stakeholders in negotiating, and explicitly reporting, reasonable compromises for trustworthy as well as cost-worthy
guidelines. The framework helps fill a transparency gap in how methodological choices in guideline development are
made. The principle, ‘when good is good enough’ can serve as a basis for this approach.
Summary: The conceptual tool ‘Efficiency-Validity Methodological Continuum’ acknowledges trade-offs between
validity and efficiency in evidence-based guideline development and allows for negotiation, guided by methodologists,
of reasonable methodological compromises among stakeholders. Collaboration among guideline stakeholders in the
development process is necessary if evidence-based guideline development is to be sustainable.
Keywords: Evidence-based practice, Guideline development, Methodology, Framework“Dans ses écrits, un sàge Italien/Dit que le mieux est
l’ennemi du bien.”
(In his writings, a wise Italian says that the best is the
enemy of the good.)
Voltaire (Francois-Marie Arouet)
Background
Evidence-based clinical practice guidelines (guidelines)
that use the most rigorous methods can help inform
clinical and policy decisions [1]. In the scientific enter-
prise, there is an imperative that we ensure new research* Correspondence: mbrouwer@mcmaster.ca
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current state of the science is well described to ethically
justify the effort and expense of new studies. Indeed,
within the guideline field, considerable effort has been
directed towards ensuring that guidelines are of high qual-
ity [2], trustworthy [3], and implementable [4]. These
goals typically translate to increasing demands on the sci-
entific and procedural rigor employed in guideline devel-
opment, and as a result, the threshold for acceptable
methodological standards continues to be raised [2-7].
The evidence-based health care movement has har-
nessed and honed the methods of the evaluation and de-
cision sciences to enhance the rigor with which we
generate, critically evaluate, interpret, and apply clinical
scientific knowledge for health care practice and policy
decisions. This has been extended in the guideline con-
text to consider the population perspective, guidelineral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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are many tools and methods to support optimal guideline
development, for example, the Appraisal of Guidelines for
Research & Evaluation (AGREE) II [2], the Guideline
International Network (GIN) Standards [6], the Institute
of Medicine (IOM) Standards [3], and Guidelines 2.0 [7].
These methods play an influential and, from many per-
spectives, a welcome role in bringing greater accountabil-
ity and credibility to practice recommendations. Such
rigor is important to minimize biases that can creep into
each step in the generation, reporting, and interpretation
of evidence considered to formulate valid recommenda-
tions that can be implemented. But perhaps it is time to
ask if the incremental price of applying escalating meth-
odological standards in all circumstances has exceeded the
incremental benefits. This paper argues for reasonable
methodological compromise to meet practical circum-
stances consistent with current implicit methodological
practice.
Discussion
Increasing demands in clinical practice guideline
development
Increased methodological expectations translate into in-
creased guideline development time, costs, and delays in
their release. For example, the AGREE II, a commonly
used quality rating instrument that also informs reporting
and development, has 23 quality criteria [2]. The IOM
Standards, a tool commissioned by the United States Con-
gress to articulate the methods for the development of
guidelines and recommendations, is composed of eight
core standards underpinning 21 components [3]. Finally,
the Guidelines 2.0 guideline development checklist com-
prises 18 themes and 146 steps [7]. Direct costs for guide-
line development can be high, as much as $200,000 per
guideline in the United States [3,5]. Are these costs for a
good-quality, trustworthy, implementable guideline worth
the added benefits under all circumstances? Past a certain
point, as yet undefined, to what extent do these addition-
al methodological expectations lead to more trustworthy
guidelines, better policy and practice, and better health
outcomes? Could failure to meet expectations lead to
greater downstream costs in the implementation of recom-
mendations that may be more prone to bias, thus negating
cost savings achieved from a more efficient methodological
approach?
These are critical and pragmatic questions for guideline
developers who create the documents, for those who use
guidelines and must wait for recommendations, for those
who fund guideline development and need to ration lim-
ited resources, and for those ultimately responsible for the
implementation of recommendations. The short answer
to these questions is that we simply do not know at what
point increasing methodological rigor leads to appreciablymore valid and implementable recommendations that, in
turn, lead to better outcomes or more affordable care.
The evidence underpinning the value of available meth-
odological tools or quality features as a means to reduce
bias varies considerably [8]. For example, the inadequacy
of blinding or allocation concealment is positively corre-
lated with larger magnitudes of effect [9]. However, the
strength of the relationship between the inclusion of a
methodological tactic and the capacity to mitigate bias
varies or is unknown. Furthermore, there is no common
evaluation framework upon which new methodological
tools are tested and no agreed upon outcomes that should
be considered in determining if a new procedural step is
worth the added time, effort, and potential expense. For
example, while increasing the perceptions of guideline
trustworthiness by clinicians is an appropriate tactic for
buy-in as a prerequisite to promoting appropriate practice
change, is it a sufficient measure upon which to justify the
time and expense of a bit of extra rigor in guideline devel-
opment procedures, or should there be a more direct link
between procedural rigor and measures such as appropri-
ate practice change and clinical outcome improvement?
The interface between guideline methodology and
stakeholder concerns
Methodologists have been the main drivers of continu-
ously increasing procedural rigor in guideline develop-
ment. However, the burden of escalating demands for
rigor has been borne by others whose perspectives need
to be taken into account to ensure timely completion of
recommendations, continued guideline funding, and on-
going participation by guideline panel members (often
voluntary). We contend that it is time for the guideline
community, as a whole, to ask whether more efficient
and affordable processes for guideline development can
be used with credible results, towards achieving a better
balance between rigor and pragmatism that addresses
the needs of all stakeholders who are affected by guide-
lines. To this end, and consistent with the spirit of trans-
parency and accountability that are at the core of an
evidence-based guideline strategy, we argue for greater
collaboration among methodologists and other guideline
developers, researchers, consumers, funders, and other
stakeholders in the application of guideline development
methods. Arguably, there should be less emphasis on
blind adherence to common, putative standards whose
generalizability and impact are uncertain.
Respecting the multi-stakeholder interests in guidelines
would require negotiations among stakeholders, guided by
methodologists, about acceptable methodological stan-
dards that are sensitive to the circumstances for which a
guideline is being developed. To facilitate negotiation
among stakeholders about methodological trade-offs in
guideline development and their potential risks to validity,
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odological Continuum (Figure 1). The goal of the tool is
not to set new standards but to provide direction on how
explicit and transparent negotiations can occur regarding
the differential application of existing standards, and how
choices may translate into variation in resource demands,
validity, and implementation. The principle of ‘when good
is good enough’ is used to support this direction.
When is a guideline ‘good enough’?
The ‘good enough’ principle is a useful paradigm for be-
ginning to address the balance between rigor and pragma-
tism in guideline development, while also taking into
account (a) the inherent level of uncertainty about the evi-
dence base and impacts associated with methodological
expectations in guideline development or (b) where evi-
dence is certain, the risk threshold for tolerating com-
promise in validity to gain efficiency. The principle of
‘good enough’ reflects the notions that continuous im-
provement will happen, that we must cope with a messy
world that defies perfection, that one starts and chooses
processes or materials whose ‘bugs’ are already known,
and that judgment is required when defining what is good
enough [10,11].
For those concerned with the erosion of quality associ-
ated with this approach, it has been observed that ‘Good
enough has nothing to do with mediocrity; it has to do
with rational choices, as opposed to compulsive behav-
ior’ [11]. Moreover, the ‘good enough’ principle is not a
radical change from what currently happens in the meth-
odological culture, as seen with the plethora of critical ap-
praisal instruments [2,12,13]. For example, it is common
within systematic reviews to use less-than-ideal methods
such as accepting language of publication limitations or
accepting literature-based, as opposed to individual patientFigure 1 The negotiation tool. The Efficiency-Validity Methodological Codata meta-analyses, despite our knowledge of validity
trade-offs [13-15]. Risks to validity when making compro-
mises can be handled by shifting towards a more explicit
discourse that involves sufficient consultation with all
stakeholders and to fill the transparency gaps in methodo-
logical choices that already exist implicitly.
The Efficiency-Validity Methodological Continuum:
a negotiating tool for methodological trade-offs for
more efficient guideline development
The circumstances that pose difficulties for highly rigor-
ous guideline development are variable enough that it
should be up to the relevant stakeholders to determine
what constitutes an acceptable trade-off between rigor
and efficiency in either developing or using a particular
guideline. Figure 1 illustrates the model upon which the
tool can be built. The guideline development approach
used should be explicit about the methodological choices
made by articulating the possible risks to validity and
the ability to use recommendations, tactics to preserve
credibility, and the gains in efficiency. As can be seen,
the extreme right and left areas of the continuum in the
figure are zones to avoid. The one extreme would arise
if the methodological choices are suboptimal or an un-
convincing rationale is provided for why some methodo-
logical steps are skipped: while potentially efficient, there
is a consensus among most stakeholders that validity is
compromised too much. For example, the failure to pro-
vide an explicit and researchable guideline question or
the failure to articulate eligibility criteria to direct the
study selection may fall into this situation. The other ex-
treme would occur in circumstances where overempha-
sis on methodological issues would require additional
expense and demand procedures where the evidence
base to support them is lacking, or where there are littlentinuum for sustainable guideline development.
Table 1 Potential factors and perspectives that could be
used in stakeholder negotiations
Factors Perspectives


















Adapted from Bach [11].
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ample, extracting data in duplicate or searching the ref-
erence lists of identified studies may fall into this
category.
Zones of ‘preference’ and ‘acceptability’ along the con-
tinuum (Figure 1) both reflect the ideal to be achieved in
developing a valid evidence-based guideline contrasted
to an approach to achieve efficiency in terms of time, ef-
fort, and costs with reasonable methodological com-
promise. The continuum implies that methods employed
to maximize efficiency through methodological shortcuts
may come with risks to validity. Conversely, striving for
maximum validity may come at an unreasonable price in
terms of expense and delay, thus compromising imple-
mentability. Most guideline developers will want to be
somewhere between these two extremes, as close to the
right (validity) as reasonably practical, with acceptable
compromises to validity and implementability to be ne-
gotiated among stakeholders. The key when choosing an
approach is transparency in terms of what compromises
are agreed to, the costs, and how this is reported.
The proposed ‘efficiency-validity trade-off continuum’
is intended to raise awareness within organizations and
among guideline sponsors and developers about the pro-
spect that, as stakeholders, they have choices to negotiate
among themselves towards credible compromises without
delegating all methodological choices to the methodolo-
gist. Where there is little research-derived information
that meets minimal standards for health care evidence,
but where there is a demand or a need for guidance, con-
sensus approaches may be most appropriate. The frame-
work here may be modified for that purpose, negotiating
an optimal balance between informal and formal consen-
sus methods [16].
How might this framework be used in practice and what
is its potential impact?
We envision the ‘efficiency-validity trade-off continuum’
as an opportunity for promoting collaborative negotiation
within multi-representative guideline development panels
at the stage of protocol development for an evidence-
based guideline to determine what is acceptable for a
given project. Questions from the good enough quality
paradigm [11] may serve as useful questions to facilitate
the discussion (Table 1). In terms of what is ‘acceptable,’
we need to be aware that trade-offs are made on behalf of
patients, the key stakeholders in the guideline enterprise
who, therefore, should be represented on the guideline de-
velopment panel where the negotiation for trade-offs is
taking place. These circumstances may include the fund-
ing available, time considerations, the urgency of the need
for guidance, and the intended use of the guideline (to ad-
vise clinical practice, influence system-level policy, incorp-
oration into decision support systems, etc.). The thresholdor limits of the boundaries for the zones of acceptability
or preference along the continuum are determined by the
negotiating partners and cannot be objectively prescribed
for everyone nor generalized to all circumstances. More-
over, one may imagine that as methodological innovations
and advancements are made that make the development
process more efficient and less expensive, this too would
shift thresholds and decisions about acceptability.
We postulate that using such a negotiating tool will
over time limit unnecessary costs and, therefore, encour-
age increased investment in guidelines; opportunities to-
wards further methodological refinement; and improved
consensus about quality, trustworthiness, implementabil-
ity, and ‘cost-worthiness’ of evidence-based guidelines.
We predict furthermore that failure to address all stake-
holder concerns around appropriate levels of investment
in guidelines that are circumstance-sensitive will gradually
erode the evidence-based guideline movement. This ero-
sion is already demonstrated through the rising popularity
and credibility of alternative, more affordable, and largely
consensus-based models and by reasonable concerns that
the efforts and costs associated with rigorous evidence-
based methods may often produce recommendations that
are not substantially different from those resulting from
less rigorous and less costly approaches [17-19].
Summary
We propose a re-examination of the trend towards ever-
increasing methodological standards for guideline develop-
ment with respect to the costs, efforts, and delays involved
for the benefits gained. We suggest that decisions about
guideline development procedures be circumstance-sensi-
tive and therefore negotiated among all stakeholders who
may be affected, rather than left solely to the research
methodologist. We offer a conceptual tool, the ‘Efficiency-
Validity Methodological Continuum,’ to help guideline
stakeholders (sponsors/payers, clinicians, methodologists,
and patient representatives) to respectfully negotiate cred-
ible compromises in methodological rigor imposed by
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mises are already being made implicitly through the use of
quality rating scales for individual studies and existing sys-
tematic reviews and guidelines, few of which are without
flaws. Based on negotiated explicit and transparent deci-
sions, guideline consumers can judge whether a guideline
has achieved a level of quality, trustworthiness, and imple-
mentability that is ‘good enough.’
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